Dear Health Care Provider,
As a prescriber who enrolled a patient in the AstraZeneca Oncology Patient Support Program (PSP) for TRUQAP™, we’re updating you with some important changes.
We’d like to remind you that the free drug component of the PSP for TRUQAP™ has officially closed on March 31st, 2025, end of day. AstraZeneca Canada will be discontinuing the free drug component of the PSP for all NEW patients enrolled after March 31st, 2025.
Details regarding the refined PSP program are outlined below:
- After March 31st, 2025 all NEW eligible patients enrolledin the PSP will still have access to:
- ✓Nursing and Educational resources.
- ✓Reimbursement navigation.
- ✓Co-pay assistance (up to 40% for patients with private insurance or who are paying out of pocket and up to 20% for patients with public insurance).
- The free drug component of the PSP for TRUQAP™ will no longer be available.
To streamline the process for new enrolments seeking the refined services above, we have introduced a new simplified enrollment form for patients meeting the eligibility criteria which include:
- Patient must be a citizen or a resident of Canada
- Patient meets Health Canada approved indication: TRUQAP (capivasertib tablets), in combination with fulvestrant, is indicated for the treatment of adult females with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy
- HR positive / HER2 negative molecular subtype (HER2 IHC score of 0, or 1+, or 2+/ISH-)
- AKT pathway alteration status of PIK3CA, and/or AKT1, and/or PTEN mutation
The following criteria may also apply depending on the payer’s coverage requirements:
- ECOG Performance Status of 0, 1, or 2
- ≤2 (0, 1, or 2) prior lines of endocrine therapy in the metastatic setting
- If the patient had 0 prior lines of endocrine therapy in the metastatic setting, they must have developed recurrence while on or within 12 months of completing adjuvant endocrine therapy
- ≤1 (0 or 1) prior line of chemotherapy for treatment (to disease progression or toxicity) in the metastatic setting
- NO progression on prior treatment with fulvestrant in either monotherapy or combination therapy
If you have any questions, please do not hesitate to contact the Patient Support Program directly at 1-877-280-6208 or enrollment@azoncologypsp.ca.
Regards,
Your Patient Care Coordinator
AstraZeneca Oncology Patient Support Program